Richard Pilnik Net Worth

The estimated Net Worth of Richard D. Pilnik is at least $1.09 Million dollars as of 23 June 2023. Mr. Pilnik owns over 38,363 units of DiaMedica Therapeutics stock worth over $1,087,313 and over the last 6 years he sold DMAC stock worth over $0. In addition, he makes $0 as Independent Chairman of the Board at DiaMedica Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Pilnik DMAC stock SEC Form 4 insiders trading

Richard has made over 7 trades of the DiaMedica Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 38,363 units of DMAC stock worth $149,999 on 23 June 2023.

The largest trade he's ever made was buying 38,363 units of DiaMedica Therapeutics stock on 23 June 2023 worth over $149,999. On average, Richard trades about 7,733 units every 97 days since 2018. As of 23 June 2023 he still owns at least 248,245 units of DiaMedica Therapeutics stock.

You can see the complete history of Mr. Pilnik stock trades at the bottom of the page.

Richard Pilnik biography

Richard D. Pilnik (Rich) serves as an Independent Chairman of the Board of DiaMedica Inc. Mr. Pilnik has been a member of DiaMedica's Board of Directors since 2009. He recently retired as Executive Vice President and President of Quintiles Commercial Solutions, a global pioneer in pharmaceutical services. Mr. Pilnik previously spent 25 years at Eli Lilly, where he held several leadership positions including Group Vice President and Chief Marketing Officer. As President of Eli Lilly Europe, Middle East and Africa and the Commonwealth of the independent States (CIS), a regional organization of former Soviet Republics, he oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region. During his tenure at Eli Lilly, Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America. Mr. Pilnik has served on the board of directors of Elan Corporation, a successful bio-pharmaceutical company focused on neurodegenerative diseases, prior to the company being acquired in 2013. He holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University. He currently sits on the board of the Duke University Fuqua School of Business and Elan Pharmaceuticals.

How old is Richard Pilnik?

Richard Pilnik is 57, he's been the Independent Chairman of the Board of DiaMedica Therapeutics since 2014. There are 1 older and 3 younger executives at DiaMedica Therapeutics. The oldest executive at DiaMedica Therapeutics Inc. is Dr. Harry W. Alcorn Jr., Pharm.D., 65, who is the Sr. VP of Clinical Operations.

What's Richard Pilnik's mailing address?

Richard's mailing address filed with the SEC is 301 CARLSON PARKWAY, SUITE 210, , MINNEAPOLIS, MN, 55305.

Insiders trading at DiaMedica Therapeutics

Over the last 6 years, insiders at DiaMedica Therapeutics have traded over $0 worth of DiaMedica Therapeutics stock and bought 7,996,631 units worth $17,281,380 . The most active insiders traders include Koch Thomas Tom Enterprise ..., Jantrill Ab Stahlberg, and David J. Wambeke. On average, DiaMedica Therapeutics executives and independent directors trade stock every 48 days with the average trade being worth of $833,934. The most recent stock trade was executed by Koch Thomas Tom Enterprise ... on 28 June 2024, trading 1,200,000 units of DMAC stock currently worth $3,000,000.

What does DiaMedica Therapeutics do?

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Complete history of Mr. Pilnik stock trades at DiaMedica Therapeutics

DiaMedica Therapeutics executives and stock owners

DiaMedica Therapeutics executives and other stock owners filed with the SEC include:

• Dietrich John Pauls MBA,
  Pres, CEO & Director
• Rick Pauls,
  President, Chief Executive Officer, Director
• Dr. Harry W. Alcorn Jr., Pharm.D.,
  Sr. VP of Clinical Operations
• Scott B. Kellen C.A.,
  CFO & Company Sec.
• James Parsons,
  Director
• Michael Giuffre,
  Independent Director
• Jerry Xiao,
  Director
• Harry Alcorn,
  Director
• Paul Papi,
  Vice President - Business Development
• Sydney Gilman,
  Vice President - Regulatory Affairs
• Scott Kellen,
  Chief Financial Officer, Corporate Secretary
• Richard Pilnik,
  Independent Chairman of the Board
• Dr. Edward G. Calamai Ph.D.,
  Consulting Head of Manufacturing
• Tanya Lewis,
  Director
• David J. Wambeke,
  Chief Business Officer
• Jantrill Ab Stahlberg,
  
• Dietrich John Pauls,
  President and CEO
• Zhenyu Xiao,
  Director
• Todd A. Verdoorn,
  Chief Scientific Officer
• Koch Thomas Tom Enterprise ...,
  
• Koch Thomas Tom Enterprise ...,
  
• Charles Pauling Semba,
  Director
• Amy L. Burroughs,
  Director
• Kirsten L Gruis,
  Chief Medical Officer
• Dominic R Cundari,
  Chief Commercial Officer
• Julie Van Orsdel Daves,
  SVP Clinical Development Oper.
• Masuoka K. Lorianne,
  Chief Medical Officer
• Richard Kuntz,
  Director